Reported 8 months ago
Eli Lilly has successfully tested the use of Zepbound, a GLP-1 weight-loss drug, in treating sleep apnea, leading to the company filing for FDA approval. This development could impact CPAP device makers like Philips and ResMed. The drug showed a significant reduction in sleep apnea incidents, with Lilly aiming to gain Medicare reimbursement through this new application, potentially influencing Medicare coverage for weight loss drugs as well.
Source: YAHOO